These findings reveal a noncanonical, lipase-independent role for ABHD5 in restraining oncogenic c-MYC signaling and highlight its potential as a therapeutic target in MYC-driven prostate cancer. This evidence concerns the gene ABHD5 and Familial prostate cancer.